Ask about this productRelated genes to: MOGAT2 antibody
- Gene:
- MOGAT2 NIH gene
- Name:
- monoacylglycerol O-acyltransferase 2
- Previous symbol:
- -
- Synonyms:
- MGAT2, DGAT2L5, FLJ22644
- Chromosome:
- 11q13.5
- Locus Type:
- gene with protein product
- Date approved:
- 2004-05-14
- Date modifiied:
- 2014-11-19
Related products to: MOGAT2 antibody
Related articles to: MOGAT2 antibody
- Metabolic dysfunction-associated liver disease (MASLD) arises from the accumulation of triglycerides within the liver. MASLD can advance to metabolic dysfunction-associated steatohepatitis (MASH), cirrhosis, and hepatocellular carcinoma. Monoacylglycerol acyltransferase 2 (MOGAT2) is essential for triglyceride synthesis and plays a significant role in regulating lipid metabolism. Here, we demonstrate the ability of a new human MOGAT 2 inhibitor, VB-85387, to inhibit the development of MASLD/MASH and further define its effects on the key metabolic pathways that progress MASH development. MASLD/MASH was induced using a methionine, choline-deficient diet (LMCD) or by streptozotocin treatment combined with high fat diet feeding (STAM-HFD). VB-85387 significantly mitigated the severity of MASLD and reduced signs of MASH in mice subjected to these two distinct diets. VB-85387-treated mice exhibited decreased fibrosis, evidenced by reduced hepatic triglyceride concentrations, hydroxyproline levels, and collagen deposition. NAS scores were consistently lower in VB-85387-treated mice across both models. VB-85387-treated mice showed induced PPARα signaling and reduced SREBP transcription, demonstrating a likely role for VB-85387 in regulating lipogenesis and fatty acid β-oxidation. STAM-HFD treated mice showed lower NF-κBp65 activation, which was associated with lower TNFα expression. IL-1β and IFNβ levels were also both reduced, suggesting VB-85387 can reduce pro-inflammatory pattern recognition receptor signaling. In addition, treatment suppressed IL-4/IL-6-dependent JAK activation. Overall, VB-85387 inhibited MASLD development by reducing liver triglyceride levels, fibrosis, and meta-inflammatory signaling. VB-85387 was as effective or superior to the MOGAT2 inhibitor phase I clinical trial drug BMS-963272 in reducing MASLD and fibrosis. VB-85387 has considerable potential for developing therapeutics targeting MASLD/MASH. - Source: PubMed
Publication date: 2026/09/01
Gallo-Ebert ChristinaWayne JoshuaBrown AlyssaNickels Joseph T - Down feathers and contour feathers are two distinct feather types with vastly different structures and functions coexisting in the same individual. However, the molecular mechanism underlying these differences remains unclear. In this study, skin tissue containing intact feather follicles was collected from four anatomically defined regions of healthy Beijing ducks () for transcriptomic sequencing: the breast and abdomen, which generate down feathers, and the wingtips and rump, which produce contour feathers. To mitigate bias arising from site-specific effects, we established paired comparisons between contour feathers and down feathers across different regions. Across all comparisons, 36 core differentially expressed genes (DEGs) were consistently identified. These encompassed nine family transcription factors across three paralogous clusters, family members ( and ), , , , cytoskeletal and sarcomeric genes (, , , ), extracellular matrix regulators (, , ), and lipid metabolism-related genes (, ), among others. Pathway enrichment analysis revealed that transcriptomic variations in different feather follicles involve gene modules functioning in positional identity, cytoskeletal organization, extracellular matrix remodeling and lipid metabolism, with potential neuroendocrine modulation. The transcriptomic dataset established here facilitates future studies on the molecular mechanisms of feather differentiation and offers a reference for molecular breeding to enhance down feather yield and quality of Beijing ducks. - Source: PubMed
Publication date: 2026/07/22
Wang WenguiGuo JiangpengWang LiangZhang MengZhang XinyeJiang XiaoyuChen TairanMei XiaohanRen XufangQu Lujiang - As a ubiquitous environmental endocrine disruptor, nonylphenol (NP) threatens aquatic organisms, driving the need for sustainable mitigation strategies. While probiotics represent promising eco-friendly supplements, their molecular mechanisms against NP toxicity remain unclear. In this study, S. meridionalis received 7-week of probiotic (Bacillus subtilis and Lactobacillus acidophilus) pretreatment followed by 15 days of NP exposure. Integrated metagenomics, transcriptomics, and metabolomics analyses, with Reverse transcription quantitative real-time PCR (RT‒qPCR) and Enzyme-linked immunosorbent assay (ELISA) validation, were performed to elucidate microbial, genetic and metabolic responses. Growth performance, including the specific growth rate (SGR) and weight gain rate (WGR), was concurrently assessed. - Source: PubMed
Publication date: 2026/07/08
Luo DeqinLu FanglianYang LianGan ZhenboZhang XianboZhao ZhenxinDong Ranran - Dietary lipids are typically ingested within complex protein-lipid matrices, where the protein source serves as a primary determinant of lipid digestion and bioavailability. However, the role of myofibrillar proteins, which are major components of meat, in influencing lipid handling and systemic lipid metabolism remains unclear. In this study, we examined the effects of four dietary protein matrices, , myofibrillar protein (MP), sarcoplasmic protein (SP), casein (CAS), and soy protein isolate (SPI) on lipid bioavailability and enterohepatic metabolism in adolescent female C57BL/6J mice. Adolescent female C57BL/6J mice received daily oral gavage of 0.2 mL protein-lipid matrices consisting of soybean oil and protein solution (1 : 1, v/v; 10 mg mL protein) for 32 days. The MP-Oil group exhibited significantly higher fecal excretion of lipids and bile acids, alongside reduced serum total cholesterol and low-density lipoprotein cholesterol (LDL-C) levels compared to the other protein groups. The MP-Oil treatment was also associated with downregulation of intestinal genes involved in lipid uptake (, ), re-esterification (, ), and chylomicron assembly (). In addition, , , , and were downregulated in the ileum but upregulated in the liver. These findings indicate a potential application of the MP matrix to reduce dietary lipid absorption by promoting bile acid binding and regulating intestinal and hepatic lipid-related gene expression. - Source: PubMed
Publication date: 2026/07/20
Zhou MengDing MengzhenWu LiliYang KunHe HuiLi Chunbao - GLP-1 therapies for obesity are limited by side effects and weight regain is common after treatment ends. Therefore, alternative treatments with new mechanisms are needed for sustained weight loss. Human MOGAT2 regulates triglyceride metabolism and its inhibition reduces weight in people with obesity, making MOGAT2 a promising target for obesity therapy. - Source: PubMed
Publication date: 2026/04/09
Corbalan J JoseJagadeesan PranaviHuang Chia-YuBeasley James RNickels Joseph T